Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women

Technology appraisal guidance
Reference number: TA160
Published: 27 October 2008
Last updated: 07 February 2018

Osteoporosis - primary prevention: Servier response to the NICE Statement of Reasons

Osteoporosis - primary prevention: Servier response to the NICE Statement of Reasons

Osteoporosis - primary prevention: Servier response to the NICE Statement of Reasons
08 December 2010
(104.17 Kb 30 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 07 December 2010